Modular Medical Inc. has announced its participation in the upcoming American Diabetes Association $(ADA.AU)$ 85th Scientific Sessions, scheduled to take place from June 20-23, 2025, in Chicago, Illinois. The company will present findings from a study investigating the pump delivery of a GLP-1R agonist, specifically exenatide, in comparison to intermittent dosing of semaglutide. The presentation, set for June 22, 2025, will feature a poster titled "Elucidating the potential benefit of pump-delivered subcutaneous GLP-1R agonist: an exploratory study in the diet-induced obese mouse." This study examines the effects of pump-delivery of a short-acting GLP-1RA on weight, food intake, and glucose tolerance in diet-induced obese mice. Results from this study will be shared during a General Poster Session at the event.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.